It is conducting clinical programs focused on oncologicals and anti-infectives.

In December 2022, Summit announced a licensing deal with a Chinese drug developer that could cost it as much as $5 billion. Summit will in-license Akeso’s (9926.HK) breakthrough bispecific antibody, ivonescimab.